Prolia
Meaning of Prolia: Unlike a bisphosphonate, denosumab leaves the skeleton once dosing stops, and bone loss resumes quickly when it does.
Definition of Prolia
Prolia is a brand name for denosumab, a laboratory-made antibody injected under the skin to treat osteoporosis and other causes of fragile bone. It blocks a signaling protein that bone-dissolving cells depend on, so less bone is broken down and density gradually rises. It is prescribed mainly for postmenopausal women and for men at increased risk of fracture.
How does it work?
Bone is dismantled and rebuilt continuously. The cells that dismantle it, osteoclasts, only mature when they receive a signal called RANK ligand from neighboring bone-building cells. Denosumab is an antibody shaped to grab that signal before it can be received, so osteoclasts fail to form and the demolition side of the cycle slows sharply. Rebuilding continues for a time against reduced removal, and measured bone density climbs. The body normally makes its own version of this blocker, called osteoprotegerin, so the drug amplifies an existing brake rather than introducing a foreign mechanism.
How does it compare with other bone drugs?
| Feature | Denosumab | Bisphosphonates |
|---|---|---|
| Type of drug | Antibody, given by injection under the skin | Small molecules, taken by mouth or by vein |
| Where it acts | Blocks the signal that creates bone-dissolving cells | Binds into bone mineral and poisons those cells as they work |
| What happens after stopping | Effect fades within months; bone turnover rebounds above baseline | Drug stays bound in bone, so effect tails off slowly |
| Kidney function | Not cleared by the kidneys | Generally avoided when kidney function is poor |
What is the same drug doing under another name?
Denosumab is sold as two separate products. Prolia treats osteoporosis at a lower dose on an infrequent schedule. Xgeva uses the same antibody at a much higher dose and far more often, to reduce fractures and other skeletal events when cancer has spread to bone, and for giant cell tumor of bone. Nothing about the molecule differs; the dose and interval do. Because the two are easily confused on a medication list, the indication is usually recorded alongside the name. Response is followed with a bone mineral density scan rather than by symptoms, since bone loss itself is silent.
Also known as
Used in a sentence
The patient received a Prolia injection as part of ongoing osteoporosis management.
Good to know
Prolia and the differently branded, higher-dose form of denosumab used in some cancer-related bone conditions are the same underlying medication marketed for different indications and dosing schedules, and bone turnover rebounds above baseline after denosumab is stopped without follow-on treatment.